Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000131419 | SCV000186399 | likely benign | Hereditary cancer-predisposing syndrome | 2024-06-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000168043 | SCV000218696 | uncertain significance | Ataxia-telangiectasia syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 826 of the ATM protein (p.Ile826Leu). This variant is present in population databases (rs587782397, gnomAD 0.009%). This missense change has been observed in individual(s) with breast cancer and/or chronic lymphocytic leukemia (PMID: 19404735, 20305132, 21993670, 28652578). ClinVar contains an entry for this variant (Variation ID: 142345). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000484154 | SCV000566330 | uncertain significance | not provided | 2023-08-04 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer, renal cancer, or leukemia, but also in unaffected controls (Paglia et al., 2010; Guarini et al., 2012; Lu et al., 2015; Navrkalova et al., 2016; Decker et al., 2017; Tiao et al., 2017); This variant is associated with the following publications: (PMID: 19404735, 21993670, 27479817, 26689913, 28779002, 28652578, 20305132) |
Counsyl | RCV000168043 | SCV000799988 | uncertain significance | Ataxia-telangiectasia syndrome | 2018-05-16 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000131419 | SCV000910809 | likely benign | Hereditary cancer-predisposing syndrome | 2016-08-06 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000779790 | SCV000916592 | uncertain significance | not specified | 2021-08-13 | criteria provided, single submitter | clinical testing | Variant summary: ATM c.2476A>C (p.Ile826Leu) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251692 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in ATM causing Ataxia-Telangiectasia (4e-05 vs 0.004), allowing no conclusion about variant significance. The variant, c.2476A>C, has been reported in the literature in individuals affected with Breast Cancer (Bernstein_2010) and CLL (Guarini_2012, LaPaglia_2009, Tiao_2017). These reports however, do not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven other ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=6) or likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Athena Diagnostics | RCV000484154 | SCV001143100 | uncertain significance | not provided | 2020-12-03 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000484154 | SCV002010840 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV001762310 | SCV002580576 | uncertain significance | Familial cancer of breast | 2021-12-27 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001762310 | SCV004203705 | uncertain significance | Familial cancer of breast | 2024-03-15 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV001762310 | SCV005084609 | likely benign | Familial cancer of breast | 2024-05-09 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. |
Natera, |
RCV000168043 | SCV001462072 | uncertain significance | Ataxia-telangiectasia syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |